Golubovskaya Vita, Berahovich Robert, Zhou Hua, Xu Shirley, Harto Hizkia, Li Le, Chao Cheng-Chi, Mao Mike Ming, Wu Lijun
Promab Biotechnologies, Richmond, CA 94806, USA.
Forevertek Biotechnology, Changsha 410003, China.
Cancers (Basel). 2017 Oct 21;9(10):139. doi: 10.3390/cancers9100139.
CD47 is a glycoprotein of the immunoglobulin superfamily that is often overexpressed in different types of hematological and solid cancer tumors and plays important role in blocking phagocytosis, increased tumor survival, metastasis and angiogenesis. In the present report, we designed CAR (chimeric antigen receptor)-T cells that bind CD47 antigen. We used ScFv (single chain variable fragment) from mouse CD47 antibody to generate CD47-CAR-T cells for targeting different cancer cell lines. CD47-CAR-T cells effectively killed ovarian, pancreatic and other cancer cells and produced high level of cytokines that correlated with expression of CD47 antigen. In addition, CD47-CAR-T cells significantly blocked BxPC3 pancreatic xenograft tumor growth after intratumoral injection into NSG mice. Moreover, we humanized mouse CD47 ScFv and showed that it effectively bound CD47 antigen. The humanized CD47-CAR-T cells also specifically killed ovarian, pancreatic, and cervical cancer cell lines and produced IL-2 that correlated with expression of CD47. Thus, CD47-CAR-T cells can be used as a novel cellular therapeutic agent for treating different types of cancer.
CD47是免疫球蛋白超家族的一种糖蛋白,在不同类型的血液系统肿瘤和实体癌肿瘤中常过度表达,在阻断吞噬作用、提高肿瘤存活率、转移和血管生成中发挥重要作用。在本报告中,我们设计了结合CD47抗原的嵌合抗原受体(CAR)-T细胞。我们使用来自小鼠CD47抗体的单链可变片段(ScFv)来生成靶向不同癌细胞系的CD47-CAR-T细胞。CD47-CAR-T细胞有效地杀死了卵巢癌、胰腺癌和其他癌细胞,并产生了与CD47抗原表达相关的高水平细胞因子。此外,将CD47-CAR-T细胞瘤内注射到NSG小鼠后,显著阻断了BxPC3胰腺异种移植瘤的生长。此外,我们对小鼠CD47 ScFv进行了人源化,并表明它能有效结合CD47抗原。人源化的CD47-CAR-T细胞也特异性地杀死了卵巢癌、胰腺癌和宫颈癌细胞系,并产生了与CD47表达相关的白细胞介素-2。因此,CD47-CAR-T细胞可作为一种新型细胞治疗剂用于治疗不同类型的癌症。